GlassScriptPhysician profile
Sary M Aristy
NPI 1922312628
$2,844.58
in general payments reported to CMS, 2019-2025
23 companies · $754 in 2025
The $754 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $152 · 2021: $40.49 · 2022: $492 · 2023: $519 · 2024: $346 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.86 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $530.99 | 2020-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $527.36 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $334.86 | 2022-2025 | |
| Abbvie INC. | $313.00 | 2020-2025 | Rinvoq, Humira |
| Genentech, INC. | $199.75 | 2019 | |
| Genentech USA, INC. | $159.35 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $114.57 | 2022 | |
| Horizon Therapeutics Plc | $103.82 | 2022-2023 | Krystexxa |
| Pfizer INC. | $80.23 | 2020-2025 | |
| Glaxosmithkline, LLC. | $77.37 | 2019-2024 | Benlysta, Nucala |
| Organon LLC | $69.86 | 2024-2025 | Hadlima |
| Genzyme Corporation | $63.02 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $42.19 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $41.70 | 2025 | Purified Cortrophin Gel |
| Ucb, INC. | $31.84 | 2024-2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.67 | 2019-2020 | |
| Radius Health, INC. | $24.80 | 2019-2024 | Tymlos |
| Pacira Pharmaceuticals Incorporated | $23.76 | 2022 | |
| Depuy Synthes Sales INC. | $19.41 | 2024 | Orthovisc |
| Invivyd INC | $18.48 | 2025 | Pemgarda |
| Scilex Pharmaceuticals INC. | $15.43 | 2024 | |
| Pacira Therapeutics, INC. | $13.79 | 2019 | |
| Lilly USA, LLC | $13.33 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sary Aristy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.